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Within the past few years, a new conceptual view of transplantation has emerged, based 
on the observation that renal transplant recipients with extremely long (27 - 29 years) graft 
survival have all had evidence of donor cells in their peripheral blood, skin, and lymph 
nodes. 1 They were thus chimeric. This led to the theory that chimerism is necessary for 
successful long term engraftment.2-4 It also led to the next logical step of attempting to 
augment chimerism by transplanting donor bone marrow at the time of organ 
transplantation. Early reports of combined organ/bone marrow transplantation have 
suggested that it is safe and is associated with reasonable outcomes.5-8 In this paper, 
we discuss the outcome in the first 30 patients undergoing combined kidney/bone 
marrow transplantation. 
MATERIALS AND METHODS 
Between December 13, 1992 and September 3D, 1994, 30 patients underwent 
combined kidney/bone marrow transplantation. Nineteen patients undergoing kidney 
transplantation alone (usually a function of lack of availability of donor bone marrow 
because of the refusal of the donor family to consent to vertebral body recovery) were 
studied as controls. Six kidney/bone marrow recipients also received pancreatic islets, 
and four received pancreases. All but one were undergoing their first transplant. Two 
of the control patients also received pancreases, and all were undergoing their first 
transplant. One patient in each group was sensitized, with a panel reactive antibody level 
over 40%. Mean recipient and donor ages, ischemia time, and quality of HLA matches 
and mismatches are listed in Table 1. 
Bone marrow was isolated from donor vertebral bodies and was infused 
intravenously at a dose of 3-5 x 108 unmodified cells/kg at the conclusion of the 
transplant procedure. 
Immunosuppression was with tacrolimus and steroids; pancreas recipients and 
occasional control patients also received azathioprine. Radiation, cytoreduction, or 
induction antilymphocyte therapy was not given to any patient. 
Blood was drawn pre- and post-transplantation for various chimerism studies 
including flow cytometry polymerase chain reaction (PCR), and fluorescent insitu 
hybridization (FISH), for V-chromosome analysis in female recipients of kidneys from male 
donors, and for immunologic studies primarily mixed lymphocyte reaction (MLR). 
RESULTS (Table 2) 
The mean follow-up for the kidney/bone marrow patients is 8.0 ± 6.4 months. 28 
(93%) have functioning kidneys, with a mean serum creatinine of 1.8 ± 0.6 mg/dl and a 
BUN of 30 ± 9 mg/dl. 
The mean follow-up for the control patients is 6.9 ± 3.7 months. 18 (95%) are 
alive, and 17 (89%) have functioning kidneys, with a mean serum creatinine of 2.3 ± 1.3 
mg/dl and a BUN of 35 ± 14 mg/dl. 
There were no differences between the 2 groups in the incidence of delayed graft 
function (17% in the kidney/bone marrow group and 16% in the control group), rejection 
(73% vs. 58%), need for OKT3 or ATG (13% vs. 11%), or CMV (13% vs. 16%). Graft vs. 
host disease was not seen in any patients. 21% of the kidney bone marrow and 22% of 
the control patients have been weaned off steroids. 
Chimerism was studied in the first 10 kidney/bone marrow and 8 control patients. 
Of 9 evaluable kidney/bone marrow patients, chimerism was seen in all, by flow 
cytometry, PCR, and/or FISH. Of 5 evaluable control patients, 3 (60%) had evidence of 
chimerism by peR and/or FISH. 
Evidence of decreasing donor specific responsiveness was seen in 2 of 9 (22% 
kidney/bone marrow and 1 of 6 (17%) control patients. In 2 patients, rejection was 
associated with an increase in donor specific responsiveness, but this was not always 
seen. 
DISCUSSION 
There have been several goals of our ongoing programs of bone marrow 
augmentation. The first has been to establish the safety of combined kidney (or other 
solid organ)/bone marrow transplantation, in terms of both short term patient and graft 
survival and function, and the absence of graft vs. host disease. Thus far, this goal 
seems to have been accomplished.5-8 The second has been to augment chimerism in 
the recipient, and, at least in the short term, this also seems to have been achieved. The 
remaining goals, of improving long term patient and graft survival, assessing the long term 
durability of chimerism and the development of donor specific hyporesponsiveness, and 
perhaps even withdrawal of chronic immunosuppression, will require many more years 
of follow-up. For now, we can say that combined kidney/bone marrow transplantation 
is straightforward, safe, is associated with reasonable patient and graft survival and 
augmentation of chimerism, and is associated with no evidence of graft vs. host disease. 
TABLE 1 
RECIPIENT AND DONOR CHARACTERISTICS 
N 
Mean Recipient Age (Years) 
Mean Donor Age (Years) 
Cold Ischemia Time (Hours) 
HLA Matches 
Mismatches 
Kidney jBone Marrow 
38.7±11.2 
29.3 ± 14.8 
23.3 ± 9.5 
2.4 ± 1.3 
3.4 ± 1.6 
TABLE 2 
RESULTS 
MEAN FOLLOW-UP - 8.0 ± 6.4 MONTHS 
Kidney jBone Marrow 
Patient Survival 100% 
Graft Survival 93% 
Serum Creatinine (mgj dl) 1.8 ± 0.6 
BUN (mgjdl) 30 ± 9 
Control 
47.7 ± 12.0 
41.1 ± 18.3 
28.1 ± 6.0 
2.5 ± 1.3 




2.3 ± 1.3 
35 ± 14 
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